PINAVERIUM BROMIDE

Possibly Marketed Outside US

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C26H41BrNO4.Br
Molecular Weight	591.416
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Br-].COC1=C(OC)C=C(C[N+]4(CCOCC[C@@H]2CC[C@H]3C[C@@H]2C3(C)C)CCOCC4)C(Br)=C1

InChI

InChIKey=IKGXLCMLVINENI-QOXGANSBSA-M

InChI=1S/C26H41BrNO4.BrH/c1-26(2)21-6-5-19(22(26)16-21)7-11-31-12-8-28(9-13-32-14-10-28)18-20-15-24(29-3)25(30-4)17-23(20)27;/h15,17,19,21-22H,5-14,16,18H2,1-4H3;1H/q+1;/p-1/t19-,21-,22-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	BrH
Molecular Weight	80.912
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C26H41BrNO4
Molecular Weight	511.512
Charge	1
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.drugbank.ca/drugs/DB09090 | http://www.medbroadcast.com/drug/getdrug/dicetel | http://e-lactancia.org/media/papers/Pinaverio-DS-2015.pdf | https://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/cps-_monographs/CPS-_(General_Monographs-_D)/DICETEL.html

Pinaverium, known under the brand name DICETEL, is a spasmolytic agent used for functional gastrointestinal disorders. It is a quaternary ammonium compound that acts as an atypical calcium antagonist to restore normal bowel function. It is shown to relieve GI spasm and pain, transit disturbances and other symptoms related to motility disorders and may be considered as effective first-lline therapy for patients with irritable bowel syndrome (IBS). Pinaverium is also used to help relieve symptoms caused by certain disorders of the gallbladder associated with secretion of bile. Pinaverium bromide is the common ingredient in formulations, mostly as oral tablets. Although it is not a currently approved drug by the FDA, pinaverium is available in over 60 countries including Canada. DICETEL® (pinaverium bromide) is a calcium antagonist which inhibits the calcium influx by blocking the voltage-dependent calcium channel at the smooth muscle cell level. It possesses a high degree of selectivity for the intestinal smooth muscle.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Voltage-gated L-type calcium channel alpha-1C subunit 44 Target ID: CHEMBL1940 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22761000 \| https://www.ncbi.nlm.nih.gov/pubmed/1313732 \| https://www.ncbi.nlm.nih.gov/pubmed/19416978 \| https://www.ncbi.nlm.nih.gov/pubmed/9360010 \| https://www.ncbi.nlm.nih.gov/pubmed/1691676	Antagonist 2849		1.75 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Irritable bowel syndrome 61 Sources: https://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/cps-_monographs/CPS-_(General_Monographs-_D)/DICETEL.html http://e-lactancia.org/media/papers/Pinaverio-DS-2015.pdf	Primary		Approved 8583	Dicetel Approved Use DICETEL® (pinaverium bromide) is indicated: - for the treatment and relief of symptoms associated with irritable bowel syndrome (IBS): abdominal pain, bowel disturbances and intestinal discomfort. - for the treatment of symptoms related to functional disorders of the biliary tract.
Biliary tract diseases 11 Sources: https://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/cps-_monographs/CPS-_(General_Monographs-_D)/DICETEL.html http://e-lactancia.org/media/papers/Pinaverio-DS-2015.pdf	Palliative		Approved 8583	Dicetel Approved Use DICETEL® (pinaverium bromide) is indicated: - for the treatment and relief of symptoms associated with irritable bowel syndrome (IBS): abdominal pain, bowel disturbances and intestinal discomfort. - for the treatment of symptoms related to functional disorders of the biliary tract.

C_max

Value	Dose	Co-administered	Analyte	Population
1714.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21308709/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:		PINAVERIUM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
1730.7 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21308709/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:		PINAVERIUM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21308709/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:		PINAVERIUM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25632806/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/25632806/	Sources: https://pubmed.ncbi.nlm.nih.gov/25632806/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
Cav1.2 58

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
Cav1.2 63	inhibitor 2237 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxOTQwIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE5MDkzMjQifX0=

PubMed

Title	Date	PubMed
Effect of probiotic Lactobacillus (Lacidofil® cap) for the prevention of antibiotic-associated diarrhea: a prospective, randomized, double-blind, multicenter study.	2010-12	21165295
[Tiaohe Ganpi Hexin Decoction in treatment of irritable bowel syndrome with diarrhea: a randomized controlled trial].	2009-09	19747435
Irritable bowel syndrome: a mild disorder; purely symptomatic treatment.	2009-04	19585728
Effect of four medications associated with gastrointestinal motility on Oddi sphincter in the rabbit.	2009	19657216
Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis.	2008-11-13	19008265
[Pinaverium bromide-induced esophageal ulcerations].	2008-06-18	18556835
[Drug treatment of irritable bowel syndrome: an unmet need].	2007-03	17374325
Quaternary ammonium derivatives as spasmolytics for irritable bowel syndrome.	2004	15579053
[New approaches to diagnosing and treating hyperkinetic biliary dyskinesia associated with chronic acalculous cholecystitis].	2004	15540426
[Randomized controlled clinical study on effect of Chinese compound changjitai in treating diarrheic irritable bowel syndrome].	2003-11	14666762
Effect of pinaverium bromide on stress-induced colonic smooth muscle contractility disorder in rats.	2003-03	12632518
[Effects of dicetel on gastrointestinal motility and vegetative dysfunction in patients with duodenal ulcer].	2003	14520942
[Current approaches to the diagnosis and treatment of irritable bowel syndrome].	2002-03-08	11881362
Contraction of human colonic circular smooth muscle cells is inhibited by the calcium channel blocker pinaverium bromide.	2001-06	11352508
Increased calcium influx is responsible for the sustained mechanical tone in colon from dystrophic (mdx) mice.	2001-05	11313313

Patents

Sample Use Guides

In Vivo Use Guide

The usual adult dosage is 50 mg three times a day (total daily dose of 150 mg). The dosage may be increased up to a maximum of 100 mg taken three times a day (maximum total daily dose of 300 mg). It is recommended that the tablet be taken with a glass of water during meals or snacks. The tablet should not be swallowed when in the lying position or just before bedtime.

Route of Administration: Oral

In Vitro Use Guide

In inflamed human colons, pinaverium (1 uM) display a significant higher efficacy than diltiazem or nicardipine to reduce cell contraction induced by CCK-8 or by KCl.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 09:29:28 GMT 2025` Edited by `admin` on `Wed Apr 02 09:29:28 GMT 2025`
Record UNII	7SCF54H12J
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DICETEL

Preferred Name

English

PINAVERIUM BROMIDE

Official Name

English

PINAVERIUM BROMIDE [MART.]

Common Name

English

4-(6-BROMOVERATRYL)-4-(2-(2-(6,6-DIMETHYL-2-NORPINYL)ETHOXY)ETHYL)MORPHOLINIUM BROMIDE

Systematic Name

English

Pinaverium bromide [WHO-DD]

Common Name

English

LAT-1717

Code

English

MORPHOLINIUM, 4-((2-BROMO-4,5-DIMETHOXYPHENYL)METHYL)-4-(2-(2-(6,6-DIMETHYLBICYCLO(3.1.1)HEPT-2-YL)ETHOXY)ETHYL)-, BROMIDE (1:1)

Systematic Name

English

pinaverium bromide [INN]

Common Name

English

PINAVERIUM BROMIDE [MI]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C333